{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T00:07:34.261907+00:00","company":{"ticker":"DARE","cik":1401914,"company_name":"Dare Bioscience, Inc."},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"9ebe0f3574da52de843096d97d8e03e7c5b410c7","cik":1401914,"ticker":"DARE","company_name":"Dare Bioscience, Inc.","filed_at":"2026-03-26T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the year ended December 31, 2025","report_date":"2026-03-26","result_type":"reported_results","revenue_text":null},"claim":"Dare Bioscience, Inc. reported financial results for the year ended December 31, 2025.","evidence_excerpt":"On March 26, 2026, Daré Bioscience, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025, a copy of which is furnished as Exhibit 99.1 to this report.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-012902","anchor_url":"https://secwatch.observer/filing/0001493152-26-012902#claim-9ebe0f3574da52de843096d97d8e03e7c5b410c7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315226012902/0001493152-26-012902-index.htm"},{"fact_type":"governance_change","fact_key":"236467a7974ffbcaa76a0f4b0899d4375645b9a4","cik":1401914,"ticker":"DARE","company_name":"Dare Bioscience, Inc.","filed_at":"2026-01-29T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-01-23","item_codes_triggered":["5.03"],"summary_text":"Filed Certificate of Designation designating 4,999,620 shares as Series A Convertible Preferred Stock, establishing powers, preferences, and rights."},"claim":"Dare Bioscience, Inc.: Filed Certificate of Designation designating 4,999,620 shares as Series A Convertible Preferred Stock, establishing powers, preferences, and rights (effective 2026-01-23).","evidence_excerpt":"On January 23, 2026, in anticipation of the initial closing of the Offering (as defined below), Daré Bioscience, Inc. (“Daré” “we,” “us,” or “our”) filed a Certificate of Designation of Series A Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, which became effective upon filing.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-004245","anchor_url":"https://secwatch.observer/filing/0001493152-26-004245#claim-236467a7974ffbcaa76a0f4b0899d4375645b9a4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/0001493152-26-004245-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"4e8595caee83d7d0f4c315bb17db7367203578fa","cik":1401914,"ticker":"DARE","company_name":"Dare Bioscience, Inc.","filed_at":"2025-02-14T23:59:59+00:00","payload":{"company_response":"hearing_requested","compliance_status":"delisting_pending","cure_deadline":"2025-02-10","deficiency_type":"market_value","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-02-13","notice_type":"delisting_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(b)(2)"]},"claim":"Dare Bioscience, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).","evidence_excerpt":"February 13, 2025, Nasdaq’s Listing Qualifications Department (the “Staff”) notified the Company that because the Company\ndid not timely regain compliance with the Minimum MVLS Rule by February 10, 2025, the Company’s co","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-006958","anchor_url":"https://secwatch.observer/filing/0001493152-25-006958#claim-4e8595caee83d7d0f4c315bb17db7367203578fa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315225006958/0001493152-25-006958-index.htm"},{"fact_type":"earnings_release","fact_key":"ad248e04c1cf17fb9ab3ce76a23601bc1bfbeaad","cik":1401914,"ticker":"DARE","company_name":"Dare Bioscience, Inc.","filed_at":"2024-05-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2024","report_date":"2024-05-14","result_type":"reported_results","revenue_text":null},"claim":"Dare Bioscience, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024, a copy of which is furnished as Exhibit 99.1 to this report.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-019087","anchor_url":"https://secwatch.observer/filing/0001493152-24-019087#claim-ad248e04c1cf17fb9ab3ce76a23601bc1bfbeaad","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224019087/0001493152-24-019087-index.htm"},{"fact_type":"material_agreement","fact_key":"ed9db288ecde3d55fc00ca6fd8795bfec8659e16","cik":1401914,"ticker":"DARE","company_name":"Dare Bioscience, Inc.","filed_at":"2024-04-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Synthetic Royalty Purchase Agreement","agreement_type":"other","counterparty":"XOMA (US) LLC","effective_date":"2024-04-29","item_codes_triggered":["1.01"],"value_text":null},"claim":"Dare Bioscience, Inc. entered into Synthetic Royalty Purchase Agreement with XOMA (US) LLC (effective 2024-04-29).","evidence_excerpt":"On April 29, 2024, Daré Bioscience, Inc. (“Daré” or the “Company”) entered into a Traditional Royalty Purchase Agreement and a Synthetic Royalty Purchase Agreement (together, the “Agreements”) with XOMA (US) LLC (“XOMA”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-017147","anchor_url":"https://secwatch.observer/filing/0001493152-24-017147#claim-ed9db288ecde3d55fc00ca6fd8795bfec8659e16","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224017147/0001493152-24-017147-index.htm"},{"fact_type":"material_agreement","fact_key":"2a37e40144520bd5cb290b5cdd4c95d5295229c5","cik":1401914,"ticker":"DARE","company_name":"Dare Bioscience, Inc.","filed_at":"2024-04-30T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Traditional Royalty Purchase Agreement","agreement_type":"other","counterparty":"XOMA (US) LLC","effective_date":"2024-04-29","item_codes_triggered":["1.01"],"value_text":"$22.0 million"},"claim":"Dare Bioscience, Inc. entered into Traditional Royalty Purchase Agreement with XOMA (US) LLC valued at $22.0 million (effective 2024-04-29).","evidence_excerpt":"On April 29, 2024, Daré Bioscience, Inc. (“Daré” or the “Company”) entered into a Traditional Royalty Purchase Agreement and a Synthetic Royalty Purchase Agreement (together, the “Agreements”) with XOMA (US) LLC (“XOMA”). In accordance with the Agreements, on April 29, 2024, XOMA paid $22.0 million to Daré","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-017147","anchor_url":"https://secwatch.observer/filing/0001493152-24-017147#claim-2a37e40144520bd5cb290b5cdd4c95d5295229c5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224017147/0001493152-24-017147-index.htm"},{"fact_type":"earnings_release","fact_key":"68acbdca4f307cbaaa31375badfe0abe6561012d","cik":1401914,"ticker":"DARE","company_name":"Dare Bioscience, Inc.","filed_at":"2024-03-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fiscal year ended December 31, 2023","report_date":"2024-03-28","result_type":"reported_results","revenue_text":null},"claim":"Dare Bioscience, Inc. reported financial results for the fiscal year ended December 31, 2023.","evidence_excerpt":"On March 28, 2024, Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the fiscal year ended December 31, 2023","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-011615","anchor_url":"https://secwatch.observer/filing/0001493152-24-011615#claim-68acbdca4f307cbaaa31375badfe0abe6561012d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224011615/0001493152-24-011615-index.htm"}]}